Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China

Yunpeng Yang, Huaqiang Zhou, Lin‐Quan Tang, Sufang Qiu, Yaqian Han, Dongmei Ji, Xiaozhong Chen, Feng Lei, S Q Qu, Bin Deng, Lusi Chen, Jian-Li Huang, Ye Guo, Zhigang Liu, Dongping Chen, Jingao Li, Xiaolei Shu, Qin Yan, Zhichao Fu, Bihui Li, Peng Zhang, Shaoqing Chen, Jinsheng Hong, Wei Yan, Xintian Qin, Shenhong Qu, Kunyu Yang, Daren Lin, Junxian Wang, Lei Yang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang